HC Wainwright Weighs in on Cytokinetics FY2026 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK) – Research analysts at HC Wainwright raised their FY2026 earnings estimates for Cytokinetics in a report released on Thursday, November 5th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will post earnings of ($5.89) per share for the year, up from their previous forecast of ($6.38). HC Wainwright has a “Buy” rating and a $140.00 price target on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.86) per share. HC Wainwright also issued estimates for Cytokinetics’ Q4 2026 earnings at ($1.37) EPS, FY2027 earnings at ($5.07) EPS and FY2028 earnings at ($1.84) EPS.

CYTK has been the subject of a number of other research reports. Royal Bank Of Canada raised their price objective on Cytokinetics from $112.00 to $113.00 and gave the company an “outperform” rating in a research report on Thursday, October 8th. Morgan Stanley raised Cytokinetics from an “overweight” rating to a “buy” rating in a report on Tuesday, September 1st. JPMorgan Chase & Co. increased their target price on Cytokinetics from $97.00 to $103.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. Citizens Jmp raised their price target on Cytokinetics from $105.00 to $110.00 and gave the company a “market outperform” rating in a report on Friday, August 7th. Finally, Leerink Partners lowered their price target on Cytokinetics from $103.00 to $100.00 and set an “outperform” rating for the company in a research report on Thursday, November 5th. Nineteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $106.67.

Cytokinetics Stock Up 2.7%

Shares of CYTK opened at $55.14 on Monday. The stock has a market cap of $6.86 billion, a P/E ratio of -9.13 and a beta of 0.45. The business’s 50 day moving average price is $65.34 and its 200-day moving average price is $69.93. Cytokinetics has a 52 week low of $53.55 and a 52 week high of $88.31.

Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.06. The business had revenue of $47.56 million for the quarter, compared to the consensus estimate of $41.88 million. During the same period in the prior year, the business posted ($2.55) EPS. Cytokinetics’s revenue for the quarter was up 2356.5% on a year-over-year basis.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CYTK. Physician Wealth Advisors Inc. grew its stake in shares of Cytokinetics by 810.2% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 446 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 397 shares during the period. V Square Quantitative Management LLC lifted its holdings in Cytokinetics by 71.5% during the third quarter. V Square Quantitative Management LLC now owns 458 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 191 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in Cytokinetics during the second quarter valued at approximately $36,000. Rockefeller Capital Management L.P. lifted its holdings in Cytokinetics by 842.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 641 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 573 shares in the last quarter. Finally, Manchester Capital Management LLC bought a new position in shares of Cytokinetics in the third quarter worth approximately $43,000.

Insider Buying and Selling at Cytokinetics

In other Cytokinetics news, CEO Robert Blum sold 7,500 shares of the business’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $62.81, for a total transaction of $471,075.00. Following the completion of the sale, the chief executive officer owned 278,544 shares of the company’s stock, valued at approximately $17,495,348.64. The trade was a 2.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Fady Malik sold 3,500 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $62.93, for a total value of $220,255.00. Following the completion of the sale, the executive vice president owned 153,902 shares of the company’s stock, valued at approximately $9,685,052.86. The trade was a 2.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 173,426 shares of company stock valued at $11,934,640. Insiders own 2.60% of the company’s stock.

About Cytokinetics

Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance.

The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.

Founded in 1997, Cytokinetics is based in South San Francisco, California.